Rights Offerings Explained: How They Work, TERP Calculation, and Whether to Participate

A rights offering is one of those corporate events that catches many retail investors off guard. You log into your brokerage one morning and see a notification: the company you own shares in is issuing new shares, and you have a limited window to purchase them at a discount before your stake gets diluted. The clock is ticking. What does this actually mean, and what are your options?

This guide breaks down everything self-directed investors need to understand about rights offerings -- how they work mechanically, how to calculate their true economic impact, what the signal content of a rights offering says about a company's health, and how to think through the participation decision without getting distracted by the surface-level "discount."

What Is a Rights Offering?

A rights offering is a method of capital-raising in which an existing publicly traded company offers its current shareholders the right -- but not the obligation -- to purchase additional newly issued shares, typically at a price below the current market price. The offer is made on a pro-rata basis, meaning shareholders receive rights in proportion to their existing holdings.

For example, if you own 300 shares and the company issues one subscription right per three existing shares, you receive 100 rights. Each right entitles you to purchase one new share at the subscription price. If the subscription price is set at a discount to the prevailing market price -- commonly 10% to 20% below -- the rights have immediate intrinsic value.

The mechanics follow a predictable timeline. The company announces the offering and sets a record date: anyone who holds shares on that date receives the rights. The stock begins trading ex-rights on the ex-rights date, meaning shares purchased after that date do not carry the right to participate. Shareholders then have a subscription period -- usually two to four weeks -- to decide whether to exercise their rights, sell them (if the offering structure allows), or let them expire.

The end goal for the company is straightforward: raise fresh capital without going through the book-building process of a traditional follow-on offering. The end goal for existing shareholders, at least in theory, is the ability to maintain their proportional ownership stake in the company rather than being involuntarily diluted by new investors purchasing shares in the open market.

Why Companies Use Rights Offerings

Companies have multiple tools available for raising equity capital: follow-on public offerings (FPOs), at-the-market programs, private placements, and rights offerings. The choice between them reveals something about the company's situation, its relationship with its shareholders, and its access to institutional capital markets.

Rights offerings carry a specific advantage that the others lack: they are pre-emptive. By giving existing shareholders first access to new shares, the company respects the concept of pre-emption rights -- the principle that current owners should have the first opportunity to avoid dilution. This is not merely courtesy. In many jurisdictions outside the United States -- particularly across Europe, Australia, and Asia -- pre-emptive rights are legally mandated or deeply embedded in corporate governance norms. A rights offering is simply the standard mechanism for equity capital raises in those markets, carrying no particular negative connotation.

In the United States, the situation is different. Pre-emptive rights are not legally required for most US-listed companies, and the follow-on offering market is highly efficient. An investment-grade company or a well-regarded growth company can raise equity capital quickly through a traditional overnight deal with institutional investors. The fact that US rights offerings are relatively rare means that when an American industrial company does one, it often signals something about its access -- or lack of access -- to the conventional follow-on market.

There are meaningful exceptions to this generalization, and they matter. Business development companies (BDCs), closed-end funds, and certain real estate investment trusts (REITs) use rights offerings as routine capital-raising mechanisms. These vehicles are structured entities with specific regulatory constraints on how they can raise capital, and a rights offering in this context carries entirely different signal content than a distressed industrial company turning to its shareholders as a lender of last resort. Understanding which category you are dealing with is the first interpretive step.

The Core Mechanics: Subscription Price, Ratio, and Dates

Every rights offering is defined by four numbers: the subscription price, the subscription ratio, the record date, and the expiration date. Getting comfortable with these is essential before any participation decision.

The subscription price is the price at which rights holders can purchase new shares. It is set at a discount to the market price, typically somewhere between 10% and 25% below the trailing market price, though extreme cases can see deeper discounts when the company is under financial stress. The discount makes the rights immediately valuable -- if the market price is sitting at $20 and the subscription price is $16, there is a $4 intrinsic value embedded in each right (adjusted for the subscription ratio).

The subscription ratio defines how many rights you need to purchase one new share, or equivalently, how many new shares you can purchase per existing share. A 1-for-3 ratio means you can buy one new share for every three shares you currently hold. A 1-for-1 ratio would double the share count, which would be highly dilutive. The ratio and the subscription price together determine how much capital the company intends to raise.

The record date is the ownership cutoff: you must own shares at the close of business on the record date to receive rights. The ex-rights date is one trading day before the record date in most markets -- this is the date after which new purchasers of the stock will not receive rights.

The subscription period is the window during which rights can be exercised. Rights that are not exercised or sold before expiration are worthless -- they do not convert to cash or shares automatically. Missing the deadline is a real cost.

TERP: The Theoretical Ex-Rights Price

The single most important concept in evaluating a rights offering is the Theoretical Ex-Rights Price, or TERP. The TERP tells you what the share price should theoretically be after the rights offering is complete and the new shares have been issued. It is the mathematical anchor that reveals whether the "discount" in a rights offering is real value or an accounting illusion.

The formula is:

TERP = (market cap before offering + new capital raised) / (total shares after offering)

Let us work through a concrete numerical example.

A company currently has 10 million shares outstanding trading at $20 per share. The market capitalization is $200 million. The company announces a 1-for-4 rights offering at a subscription price of $16 per share.

New shares to be issued: 10 million divided by 4 = 2.5 million new shares.

New capital raised: 2.5 million shares multiplied by $16 per share = $40 million.

Total shares after the offering: 10 million plus 2.5 million = 12.5 million shares.

Total company value after the offering: $200 million plus $40 million = $240 million.

TERP = $240 million divided by 12.5 million shares = $19.20 per share.

Notice what happened. Before the offering, the stock traded at $20. After the offering, it should theoretically trade at $19.20. The stock did not trade lower because the company destroyed value -- it traded lower because new shares were issued at a below-market price, diluting the per-share value across a larger share base. The $16 subscription price is not a bargain in absolute terms; it is a discount relative to the post-offering price.

The value of one right can be derived from this: the right to buy one new share at $16 when the TERP is $19.20 means each right is theoretically worth $19.20 minus $16.00 = $3.20. If you held four existing shares, you received four rights (to buy one new share at $16), and the value of those four rights ($12.80 in total) exactly offsets the decline in value of your four existing shares as the price moved from $20 to $19.20 (a $0.80 loss per share, or $3.20 total across four shares).

The math is clean and intentional. Rights offerings are designed so that participating shareholders who exercise all their rights end up in exactly the same economic position they were in before the offering. You own more shares at a lower price, but your total investment value is unchanged. The rights offering, by itself, neither creates nor destroys shareholder wealth.

What Actually Determines Value: Use of Proceeds

If the rights offering itself is wealth-neutral, the real question becomes: what will the company do with the capital it raises?

This is where the economic analysis diverges from the mechanical analysis. The capital raised through a rights offering is not free -- it costs something in terms of dilution, underwriting fees, and management time. For that capital deployment to be value-creating, the company must deploy it at a return above its cost of capital.

A rights offering that funds a high-return acquisition or a capacity expansion project at a company with strong competitive advantages is a different animal entirely from a rights offering that is used to pay down debt at a company that is fighting for survival. The same mechanical process can be associated with either value creation or value destruction, depending entirely on what happens after the capital is raised.

This is why the press release announcing a rights offering deserves careful reading. Pay particular attention to the stated use of proceeds, the company's existing debt load and near-term maturities, and any guidance or context around why the company is raising capital now rather than later. Companies that are raising capital from a position of strength tend to have clear, offensive-sounding use of proceeds -- growth investment, accretive acquisitions. Companies that are raising capital defensively tend to have vague or defensive-sounding language about "strengthening the balance sheet" or "providing financial flexibility."

Subscription Rights Trading

Not all rights offerings are structured the same way with respect to transferability. In many rights offerings -- particularly in the United States -- rights are transferable, meaning shareholders can sell them in the open market during the subscription period rather than exercising them.

Transferable rights trade as separate securities on the exchange during the subscription period. Their market price should reflect their intrinsic value: the spread between the current stock price and the subscription price, adjusted for the subscription ratio. Using the earlier example, if the stock is trading at $19.50 and the subscription price is $16.00 on a 1-for-4 ratio, each right should theoretically be worth approximately $3.50 divided by 4, or about $0.875 per right. In practice, the market price for rights may deviate from theoretical value due to trading friction, illiquidity, and time value as the expiration approaches.

The existence of a trading market for rights matters because it provides an exit option for shareholders who cannot or do not want to inject more capital into a particular position. A shareholder who received 1,000 rights can sell those rights in the market, capturing their intrinsic value without needing to send additional cash to the company. This is the rational response for a shareholder who is constrained on capital or who has changed their view of the company's prospects.

The worst outcome for a shareholder is to do nothing -- to neither exercise nor sell the rights before expiration. In that case, the rights expire worthless, the shareholder has not participated in the new share issuance, and their ownership percentage has been diluted by the shares purchased by other participants. The shareholder who lets rights expire has effectively gifted value to the exercising shareholders.

In non-transferable rights offerings, the sell-the-rights option is unavailable. This structure is less common but does appear, particularly in some international markets and in certain US closed-end fund offerings. In these cases, the decision is binary: exercise or accept dilution.

Standby Underwriters and Firm-Commitment Structures

Companies undertaking rights offerings often want certainty that they will raise the full amount of capital regardless of how many shareholders choose to exercise. This is where standby underwriting comes in.

In a standby underwritten rights offering, one or more investment banks agree to purchase any shares that are not subscribed by existing shareholders. If only 70% of rights are exercised by the end of the subscription period, the standby underwriter purchases the remaining 30% of the new shares at the subscription price. This guarantees the company that it will receive the full proceeds regardless of take-up.

From the company's perspective, standby underwriting eliminates execution risk. The capital raise is effectively certain from the moment the standby agreement is signed. From the underwriter's perspective, standby underwriting carries real risk -- they are essentially short a put on the stock at the subscription price, and if the stock price falls significantly during the subscription period, they may be required to purchase a large block of shares at above-market prices.

Underwriting fees for standby arrangements reflect this risk. Standby fees are typically higher than straight follow-on offering fees because the underwriter is providing a guarantee rather than simply running a book-building process. The standby fee is a real cost to the company and thus to existing shareholders -- it reduces the net capital raised relative to gross proceeds.

Some rights offerings include over-subscription privileges, which allow shareholders who want to purchase more than their pro-rata allocation to apply for additional shares if other shareholders fail to exercise. This mechanism can reduce the amount of shares the standby underwriter needs to absorb, lowering the company's underwriting cost.

Rights Offerings as Distress Signals in the US Market

For US-listed industrial companies, REITs outside of routine capital cycles, and operating businesses generally, a rights offering announcement warrants careful scrutiny. The US equity capital markets are deep and liquid. A company with strong fundamentals, reasonable leverage, and credible growth prospects can almost always complete a traditional follow-on offering in a matter of days by marketing to institutional investors.

When a US operating company cannot access the traditional follow-on market -- or can only access it at terms that are deeply punitive -- it may turn to its existing shareholders through a rights offering. This is rational for the company in the sense that existing shareholders have a built-in motivation to protect their existing stake from dilution, and the pre-emptive framing of a rights offering makes participation psychologically easier to justify.

But this dynamic also means the rights offering announcement itself can be read as a signal: the company may have approached the conventional market and found unfavorable terms. The rights offering is a fallback, not a first choice. This does not mean a rights offering is always associated with imminent financial distress -- companies can be in challenging but stable situations -- but it does mean the bar for independent analysis is higher, not lower, when a US operating company announces one.

Specifically, research the company's credit metrics, near-term debt maturities, covenant positions, and operating cash flow trends before forming any view on participation. The capital raise may be defensive, and defensive capital raises sometimes stabilize a company and sometimes delay an inevitable restructuring.

When Rights Offerings Carry No Distress Signal

The distress-signal framework does not apply uniformly. BDCs and closed-end funds are the clearest exceptions.

Business development companies are regulated investment vehicles that lend to or invest in middle-market companies. They are required by law to distribute most of their income as dividends, which limits retained earnings. To grow their asset base and maintain diversification, BDCs routinely need to raise new equity capital. Rights offerings are a standard, expected mechanism for BDC capital raises, and a BDC rights offering announcement is generally not a signal of financial distress -- it is normal business activity.

Closed-end funds face a structurally similar situation. They have fixed share counts and trade at prices that may be at a premium or discount to net asset value (NAV). A rights offering at a price below NAV is dilutive to existing shareholders, but the decision to undertake it reflects the fund manager's interest in growing the asset base and fee revenue, not necessarily financial pressure on the fund itself.

REITs occupy a middle ground. Many REITs operate in capital-intensive businesses where periodic equity raises are part of the business model, and some use rights offerings as routine capital management tools. Others, particularly smaller or more leveraged REITs, may use rights offerings when other options have narrowed. The type of REIT, its leverage profile, and the current state of its property sector all inform interpretation.

The key discipline is to evaluate the structure of the entity and the context of the capital raise before applying any interpretation to the offering announcement.

Participating vs. Not Participating: The Break-Even Framework

If you hold shares in a company that has announced a rights offering, you face a three-way decision: exercise your rights and subscribe to new shares, sell your rights in the open market (if transferable), or allow your rights to expire. Each path has a different economic outcome.

Exercising your rights is the path to maintaining your proportional ownership. As the TERP analysis showed, exercising at the subscription price leaves your total economic position unchanged in the immediate term -- more shares at a lower per-share price, same aggregate value. Whether exercising is a good decision beyond the mechanical neutrality depends entirely on whether the company will deploy the capital productively.

The participation decision is really a forward-looking question about the company: are you willing to commit additional capital to this business at this point in time? If your analysis of the company is positive -- you believe the capital will be deployed at acceptable returns, the balance sheet strengthens meaningfully, and the operational trajectory is sound -- then exercising is consistent with your existing investment thesis. You are increasing your position at a slight mechanical discount.

If your view of the company has deteriorated, or if the rights offering has caused you to revisit your thesis and you now hold a less constructive view, then exercising means committing new capital to a position you would not otherwise add to at current prices. In that case, selling your rights captures the intrinsic value without requiring additional capital commitment. The rights represent real economic value regardless of what you choose to do with the underlying position.

The one path with no rational defense is passive expiration of transferable rights. Letting transferable rights expire without exercise or sale is equivalent to leaving cash on the table. The rights have intrinsic value, and failure to capture that value -- either through exercise or sale -- is a pure economic loss.

Non-participating shareholders who cannot or do not sell their rights will see their percentage ownership diluted and, in the immediate aftermath of the offering, will see their per-share price decline toward the TERP. Their aggregate portfolio value is unchanged only in the sense that the dilution loss and the rights value offset each other -- but if the rights expire worthless, that offset disappears entirely.

How to Research a Rights Offering

When a rights offering is announced, the analysis starts with the SEC filing. The Form S-1 or Form F-3 registration statement (for foreign private issuers) and the associated prospectus will contain the complete terms: subscription price, subscription ratio, record date, expiration date, transferability, standby commitments, and use of proceeds.

Use of proceeds is the single most important section. It tells you why the company is raising capital, how the funds will be deployed, and whether there is any financial urgency embedded in the language. Read it carefully. Compare the capital being raised against the company's current debt load and near-term maturities to assess whether the offering is offensive or defensive.

The subscription price relative to TERP tells you the mechanical terms but not the investment quality. The intrinsic value of the rights -- based on the spread between market price and subscription price adjusted for the ratio -- sets a floor on the value of your rights if transferable, but it says nothing about whether the company is worth owning going forward.

Equity Rank's valuation tools can support your independent research into whether the underlying company warrants the additional capital commitment. Running a SAVE score analysis on the company, reviewing its fair value estimates across multiple valuation methods, and examining its options market activity (for any available context around institutional positioning) can all inform your view of the company's fundamental quality before the subscription deadline. None of this replaces your own judgment, but having institutional-depth analysis available in a single platform means you can form a more complete research view in the limited time the subscription window provides.

You can run a full analysis on any stock at equity-rank.com and start a 7-day free trial to access the complete suite of valuation models, SAVE scoring, and options analysis.

Summary

Rights offerings give existing shareholders the opportunity to purchase new shares at a discount before being diluted by new issuance. The TERP framework makes clear that the discount is not free money -- it reflects the mechanical dilution of the existing share base, and a shareholder who fully participates ends up in the same economic position as before. The rights offering itself does not create or destroy value; what matters is whether the company deploys the raised capital productively.

In the United States, rights offerings by operating companies can signal constrained access to conventional capital markets and warrant elevated scrutiny. In regulated vehicles like BDCs and closed-end funds, rights offerings are routine and carry no such signal. Whether to participate depends not on the mechanics of the discount but on your forward-looking view of the company and its use of proceeds. Shareholders holding transferable rights should never let them expire unexercised -- the rights have real economic value that disappears at expiration if not captured.

Disclaimer: directional accuracy figures referenced in Equity Rank simulations are based on model simulations, not live trading results. Nothing on this page constitutes investment advice or a recommendation to purchase or sell any security.